HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
HAEMONETICS CORP
Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $5.43B
- P/E (TTM)
- 57.9
- Dividend yield
- –
HAEMONETICS CORP revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | $588.30M | $564.27M | $456.29M | $381.71M | – | – | – | – | – | – | 44.1% | +4.3% |
| Plasma | $524.46M | $535.43M | $569.54M | $499.92M | – | – | – | – | – | – | 39.3% | -2.0% |
| Blood Center | $221.27M | $261.12M | $283.23M | $287.03M | – | – | – | – | – | – | 16.6% | -15.3% |
| Business Unit | – | – | $1.29B | $1.15B | $972.66M | – | – | – | – | – | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma | $184.80M | $184.51M | $181.97M | $124.75M | $183.13M | $172.46M | $225.35M | $180.30M | – | – | +0.2% |
| Hospital | $103.74M | $88.98M | $52.20M | $29.42M | $129.78M | $84.07M | $80.67M | – | – | – | +16.6% |
| Blood Center | $49.98M | $52.82M | $42.37M | $64.27M | $136.69M | $141.96M | $159.80M | $163.63M | – | – | -5.4% |
| Japan | – | – | – | – | – | – | $225.35M | $180.30M | $146.99M | $43.04M | – |
| Hospital | – | – | – | – | – | $84.07M | $80.67M | $76.34M | $67.26M | $141.43M | – |
| North America Plasma | – | – | – | – | – | – | – | $167.21M | $129.70M | $109.89M | – |
| Blood Center | – | – | – | – | – | – | $159.80M | $163.63M | $170.17M | $74.88M | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | $588.30M | $564.27M | $456.29M | – | – | – | – | – | – | – | 44.1% | +4.3% |
| Blood Center | $221.27M | $261.12M | $283.23M | – | – | – | – | – | – | – | 16.6% | -15.3% |
| Blood Center | – | – | – | $226.82M | $236.16M | $239.61M | $252.83M | $269.20M | $284.90M | $303.89M | – | – |
| Plasma | – | – | – | $563.73M | $427.61M | $414.27M | $537.23M | $501.84M | $435.96M | $410.73M | – | – |
| Cell Processing | – | – | – | – | – | – | – | – | $107.56M | $105.38M | – | – |
| Hemostasis Management | – | – | – | – | – | – | – | – | $75.50M | $66.12M | – | – |
| Hospital | – | – | – | $378.11M | $329.43M | $216.58M | $198.42M | $196.54M | $183.07M | $171.50M | – | – |
| Service [Member] | – | – | $21.61M | $20.04M | $20.53M | $20.76M | $19.83M | $19.91M | $20.57M | – | – | – |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $982.18M | $1.01B | $970.01M | $842.90M | $639.32M | $522.61M | $646.20M | $606.85M | $548.73M | $522.69M | 73.6% | -2.8% |
| Europe | $185.02M | $175.66M | $160.14M | $156.68M | $163.52M | $159.08M | $153.35M | $164.50M | $164.23M | $166.01M | 13.9% | +5.3% |
| Rest of Asia | $87.21M | $92.31M | $107.54M | $104.14M | $110.80M | $105.82M | $109.30M | $118.70M | $115.13M | $109.86M | 6.5% | -5.5% |
| Japan | $68.20M | $62.41M | $58.09M | $61.30M | $75.56M | $77.68M | $72.22M | $69.91M | $67.32M | $79.27M | 5.1% | +9.3% |
| Other | $11.42M | $19.54M | $13.28M | $3.65M | $3.99M | $5.28M | $7.42M | $7.62M | $8.52M | $8.30M | 0.9% | -41.5% |
From the segment and revenue-disaggregation notes of Haemonetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.